期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨保护素与心血管疾病研究进展 被引量：3

Research progress of osteoprotegerin in cardiovascular disease
原文传递
导出
摘要 骨保护素(OPG)是由成骨细胞分泌的一种无跨膜结构的可溶性糖蛋白,是由Simonst等首次发现的一个肿瘤坏死因子(TNF)受体超家族的新成员。OPG是核因子-κB受体活化因子配体(RANKL)的诱导受体,OPG通过与核因子-κB受体活化因子(RANK)的竞争性结合来阻断RANKL与RANK的结合从而抑制破骨细胞(OC)的分化成熟并诱导OC的凋亡,OPG在骨形成和骨吸收方面具有重要作用。近年来的研究表明,OPG在心血管系统中发挥着重要的调控作用,已成为心血管疾病的研究热点。现将OPG与心血管疾病的相关研究进展做相关阐述。 Osteoprotegerin （OPG）, a new member of tumor necrosis factor （TNF） receptor superfamily, is a soluble non-transmembrane glycoprotein secreted by osteoblasts, which was first discovered by Simonst. OPG is the receptor activator of nuclear factor-κB factor ligand （RANKL） induced receptor, competitively inhibits the combination of RANKL and receptor activator of NF-κB （RANK）. It can inhibit osteoclast＇s （OC） differentiation, maturation and induce osteoclast apoptosis. OPG plays an important role in the formation and resorption of bone. Recent studies show that OPG plays important roles in the regulation of the cardiovascular system, and it has become a hot research topic in cardiovascular disease. In this review, we will do the related elaboration of research progress of OPG and cardiovascular diseases.
作者 冯模强 吕湛
机构地区 川北医学院附属医院心血管内科
出处 《中华临床医师杂志（电子版）》 CAS 2013年第24期272-274,共3页 Chinese Journal of Clinicians(Electronic Edition)
关键词 骨保护素 心血管疾病 细胞凋亡 Osteoprotegerin Cardiovascular diseases Apoptosis
分类号 R54 [医药卫生—心血管疾病]
  • 相关文献

参考文献29

  • 1Simonet WS,Laeey DL,Dunstan CR. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density[J].{H}CELL,1997.309-319.
  • 2Anderson DM,Maraskovasky E,BiHingsley WL. A homologue of the TNF receptor and its ligand enchance T-cell growth and dendritic cell function[J].{H}NATURE,1997.175-179.
  • 3Kostenuik PJ,Nguyen HQ,McCabe J. Denosumab,a fully human monoclonal antibody to RANKL,inhibits bone resorption and increases BMD in knock-in mice that express chimeric(murine/human)RANKL[J].{H}Journal of Bone and Mineral Research,2009.182-195.
  • 4Darnay BG,Haridas V. Characterization of the intra-cellular do-main of receptor activator of NF-κB(RANK)[J].{H}Journal of Biological Chemistry,1998.20551-20555.
  • 5St?pień E,Wypasek E,Stopyra K. Increased levels of bone remodeling biomarkers(osteoprotegerin and osteopontin)in hypertensive individuals[J].{H}CLINICAL BIOCHEMISTRY,2011.826-831.
  • 6Blazquez-Medela AM,Garcia-Ortiz L,Gomez-Marcos MA. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes[J].{H}European Journal of Clinical Investigation,2012.548-556.
  • 7徐美林,张晓艳,张超,魏璇.血清骨保护素与冠状动脉病变程度的关系研究[J].中华临床医师杂志（电子版）,2012,6(13):45-48. 被引量：13
  • 8Zauli G,Coral ini F,Bossi F. Osteoprotegerin increases leukocyteadhesion to endothelial cells[J].{H}Blood,2007.536-543.
  • 9Stefanescu R,Bassett D,Modarresi R. Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endotheli-al cells,mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis[J].{H}Blood,2008.340-349.
  • 10Weiss RM,Lund DD,Chu Y. PLoS One.Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice[J].PLoS One,2013.e65201.

二级参考文献29

  • 1罗助荣,张克己,郑磊磊,徐高阳,谢菁菁,林毅,盖晓波.血清骨保护素、可溶性核因子κB受体活化因子配体与急性冠状动脉综合征相关性研究[J].中华临床医师杂志（电子版）,2011,5(10):2886-2889. 被引量：8
  • 2李占全.冠状动脉造影与临床[M]沈阳:辽宁科学技术出版社,200150-56.
  • 3Gensini GG. A more meaningful scoring systemfor determining the severity of coronary heart disease[J].American Journal of Cardiology,1983.606-609.doi:10.1016/S0002-9149(83)80105-2.
  • 4Hofbauer LC,Shui C,Riggs BL. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells[J].Biochemical and Biophysical Research Communications,2001.334-339.
  • 5Malyankar UM,Scatena M,Suchland KL. Osteoprotegerin is an alpha vbeta 3-induced,NF-kappa B-dependent survival factor for endothelial cells[J].Journal of Biological Chemistry,2000.20959-20962.
  • 6Bennett BJ,Scatena M,kirk EA. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice arterioscler[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2006.2117-2124.
  • 7Price PA,June HH,Buckley JR. Osteoprotegerin inhibits artery calcification induced bywarfarin and by vitamin D[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2001.1610-1616.
  • 8Schoppet M,Al-Fakhri N,Franke FE. Localization of osteoprotegerin,tumor necrosis factor-related apoptosis-inducing ligand,and receptor activator of nuclear factor-kappaB ligand in Monckeberg′s sclerosis and atherosclerosis[J].Journal of Clinical Endocrinology and Metabolism,2004.4104-4112.
  • 9Sandberg WJ,Yndestad A,Qie E. Enhanced T-cell expression of RANK ligand in acute coronary syndrome:possible role in plaque destabilization[J].Arteriosclerosis,Thrombosis,and Vascular Biology,2006.857-863.
  • 10Shuichi J,Yuji I,At sushi S. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease[J].Circulation,2002.1192-1194.

共引文献14

同被引文献31

  • 1谢钦菁,罗助荣.骨保护素作为预测心血管疾病发病率和死亡率的新标志物的研究进展[J].中华临床医师杂志（电子版）,2011,5(10):2963-2966. 被引量：5
  • 2Malliga D E,Wagner D,Fahrleitner-Pammer A. The role of osteo- protegerin (OPG) receptor activator for nuclear factor kappaB lig- and (RANKL) in cardiovascular pathology-a review[J]. Wien Med Wochenschr, 2011,161 (23/24) : 565 -- 570.
  • 3Simonet W S,Lacey D L,Dunstan C R,et al. Osteoprotegerin:a no- vel secreted protein involved in the regulation of bone density[J]. Cell, 1997,89(2):309--319.
  • 4Kong Y Y,Yoshida H,Sarosi I,et al. OPGL is a key regulator of osteoclastogenesis,lymphocyte development and lymph-node orga- nogenesis[J]. Nature, 1999,397(6717) :315--323.
  • 5Lacey D L,Timms E,Tan H L,et al. Osteoprotegerin ligand is a cy- tokine that regulates osteoclast differentiation and activation[J]. Cell, 1998,93(2): 165 -- 176.
  • 6Fuernau G, Zaehringer S, Eitel I, et al. Osteoprotegerin in ST eleva tion myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging[J]. Int J Cardiol,2013,167(5):2134 2139.
  • 7Jono S, Otsuki S, Higashikuni Y, et al. Serum osteoprotegerin levels and long-term prognosis in subjects with stable coronary artery dis ease[J].J Thromb Haemost,2010,8(6):1170 1175.
  • 8Venuraju S M, Yerramasu A, Corder R, et al. Osteoprotegerin as a predictor o{ coronary artery disease and cardiovascular mortality and morbidity[J]. J Am Coll Cardiol,2010,55(19):2049--2061.
  • 9Ren M Y,Sui S J ,Zhang Y, et al. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coro- nary syndrome[J].Acta Cardiol,2008,63(5) :615--622.
  • 10Yang Q, Lu S, Chen Y, et al. Plasma osteoprotegerin levels and long term prognosis in patients with intermediate coronary artery lesions[J]. Clin Cardiol,2011,34(7) :447--453.

引证文献3

二级引证文献14

中华临床医师杂志（电子版）
2013年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部